Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 105.6% in the 4th quarter, HoldingsChannel reports. The firm owned 50,897 shares of the company’s stock after purchasing an additional 26,145 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Keros Therapeutics were worth $806,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of KROS. AlphaQuest LLC boosted its stake in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC grew its holdings in Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics during the 4th quarter worth approximately $90,000. Exchange Traded Concepts LLC purchased a new stake in shares of Keros Therapeutics in the 4th quarter valued at approximately $99,000. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock valued at $116,000 after purchasing an additional 4,976 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $13.47 on Wednesday. The company has a market capitalization of $547.08 million, a P/E ratio of -2.59 and a beta of 1.32. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The stock has a 50-day simple moving average of $12.27 and a 200-day simple moving average of $23.83.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the previous year, the company posted ($1.21) earnings per share. As a group, analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Oppenheimer decreased their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Wells Fargo & Company cut their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Scotiabank lowered their price objective on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating for the company in a research report on Monday. HC Wainwright dropped their price objective on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, Piper Sandler decreased their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $37.00.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 22.90% of the company’s stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.